AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 192 min read$LLY

At Week 12, 81% of children in Lilly's ulcerative colitis trial responded to treatment

Lilly reported positive results from its SHINE-2 trial, showing 81% of pediatric ulcerative colitis patients responded to Omvoh (mirikizumab) treatment. Key outcomes included 50% clinical remission and 50% corticosteroid-free remission. Lilly plans to submit these data to regulators for potential label expansion. Omvoh is currently approved for adults with ulcerative colitis.

Original reporting
stocktitan.net
Published Oct 19, 2026, 8:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The data suggest a high likelihood of label expansion, which could add a new revenue stream and improve Lilly's growth outlook.

02

Market read

Positive pediatric trial results are likely to boost Lilly's stock and influence the biotech sector.

03

What to watch

Potential competition from other IL-23 drugs and the modest size of the pediatric market

Relevance 7/10Novelty 9/10Timing: today

Background

Lilly announced Phase 3 results for its IL-23p19 inhibitor Omvoh (mirikizumab) in pediatric ulcerative colitis, a first for this indication.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Lilly's Phase 3 SHINE-2 trial in pediatric ulcerative colitis showed 81% response at Week 12 and strong remission rates at Week 52.

Expected impact

potential upside as market prices in likely regulatory approval for pediatric use

Evidence & confidence

Efficacy and safety results exceed expectations and open a new market segment.

Market effects

Sector

strengthens outlook for biotech firms developing IL-23 inhibitors and pediatric IBD therapies

Regional

positive for US biotech sector and may boost related stocks in the S&P 500 Health Care index

Global

adds momentum to global IBD drug pipeline developments

Counterpoint

What could challenge this read

If regulatory hurdles delay approval, the stock could face disappointment despite strong data

Key entities

  • company
    Eli Lilly and Company

    Pharmaceutical company developing Omvoh for ulcerative colitis.

  • drug
    Omvoh (mirikizumab)

    IL-23p19 antagonist evaluated in the SHINE-2 pediatric trial.

Read at source← All news

StoryLilly reports positive Phase 3 pediatric ulcerative colitis trial results for Omvoh

Related articles

OCT 19
$LLYMed

Lilly reports positive pediatric ulcerative colitis trial data

Eli Lilly (NYSE:LLY) reported that its drug Omvoh met the primary endpoint in a Phase 3 study for pediatric ulcerative colitis. The SHINE-2 study showed 81% of patients achieved clinical response at Week 12, with 50% of responders in clinical remission at Week 52. The company plans to submit the data to global regulators for potential label expansion. Omvoh is already approved for adults in 47 countries.

investing.com2 min
OCT 19
$LLYHigh

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Eli Lilly's Omvoh (mirikizumab-mrkz) met the primary endpoint of clinical remission in a Phase 3 study for pediatric ulcerative colitis, with 50% of responders achieving remission at one year. The company plans to submit these data to regulators for potential label expansion. Omvoh is currently approved for adults with the condition.

prnewswire.com2 min
OCT 19
$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

european-biotechnology.com3 min